Overview

Ketamine for Reduction of Alcoholic Relapse

Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. Primary endpoints will be % days abstinent at 6 months and relapse rates at 6 months. Secondary endpoints include depressive symptoms, craving, quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Treatments:
Ethanol
Ketamine